Inflammatory bowel disease in children

Current Problems in Pediatric and Adolescent Health Care

Volumn 32, Issue 4, 2002, Pages 108-132

  Kim, Sandra ^a   Ferry, George ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PREDNISONE; PURINE DERIVATIVE; QUINOLONE DERIVATIVE; RECOMBINANT INTERLEUKIN 10; SALAZOSULFAPYRIDINE; STEROID; SULFAPYRIDINE; THIOGUANINE DERIVATIVE; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ALLERGIC REACTION; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DIGESTIVE TRACT ENDOSCOPY; DOSE RESPONSE; DRUG METABOLISM; DRUG STRUCTURE; ENTERITIS; GENETIC ANALYSIS; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LIVER TOXICITY; NAUSEA AND VOMITING; NEUROTOXICITY; NUTRITIONAL HEALTH; OLIGOSPERMIA; PANCREATITIS; PATHOGENESIS; PNEUMONIA; PREVALENCE; PSYCHOLOGICAL ASPECT; RADIODIAGNOSIS; RASH; SEROLOGY; SEX DIFFERENCE; STRUCTURE ACTIVITY RELATION; ULCERATIVE COLITIS; CHILD; GENETIC PREDISPOSITION; GENETICS; NUTRITIONAL DISORDER; PATHOLOGY; PRESCHOOL CHILD; REVIEW;

CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; NUTRITION DISORDERS; PREVALENCE;

EID: 0036525952     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: 10.1067/mps.2002.122638     Document Type: Article

References (123)

1. Kirsner JB. Historical aspects of inflammatory bowel disease. J Clin Gastroenterology 1988;10:286-97.
2. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathological and clinical entity. JAMA 1932;99:1323-9.
3. Sandler RS, Eisen GM. Epidemiology of inflammatory bowel disease. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 89-112.
4. Shashidar H, Integlia MJ, Grand RJ. Clinical manifestations of pediatric inflammatory bowel disease. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 326-34.
5. Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 153-78.
6. Mayer L. Current concepts of inflammatory bowel disease: etiology and pathogenesis. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 280-98.
7. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92(Suppl 12):S5-11.
8. El-Zaatari FA, Naser SA, Hulten K, et al. Characterization of Mycobacteria paratuberculosis p36 antigen and its seroreactivities in Crohn's disease. Curr Microbiol 1999;39:115-9.
9. Van Kruiningen HJ. Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. In Kirsner JB, editor. Inflammatory bowel diseases 5th ed. Philadelphia: WB Saunders; 2000. p. 183-91.
10. Montgomery SM, Morris DL, Pounder RE, et al. Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. Gastroenterology 1999;116:796-803.
11. Robertson DJ, Sandler RH. Measles virus and Crohn's disease: a critical appraisal of the current literature. Inflamm Bowel Dis 2001;7:51-7.
12. Afzal MA, Minor PD, Schild GC. Clinical safety of measles, mumps, and rubella vaccines. Bull World Health Organ 2000;78:199-204.
13. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of enteroadherent E. coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13.
14. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000;119:23-31.
15. Elson CO. The immunology of inflammatory bowel disease. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 208-39.
16. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
17. MacDonald TT, Monteleone G, Pender SLF. Recent Developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000;51:2-9.
18. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med 2000;51:289-98.
19. Miner PB. Clinical features, course, laboratory findings, and complications in ulcerative colitis. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 299-304.
20. Elson CO, Cong Y, Brandwein S, et al. Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann NY Acad Sci 1998;859:85-95.
21. Strober W, Ludviksson BR, Fuss IJ. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn's disease. Ann Intern Med 1998; 128:848-56.
22. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmstead County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998;114:1161-8.
23. Loftus EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmstead County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-43.
24. Farrokhyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001;36:2-15.
25. Yang SK, Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001;7:260-70.
26. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Diseases. Gut 1996;39:690-7.
27. Lindeberg E, Lindquist B, Holmquist L, Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995. JPGN 2000;30:259-64.
28. Hassan K, Cowan FJ, Jenkins HR. The incidence of childhood inflammatory bowel disease in Wales. Eur J Pediatrics 2000;159:261-3.
29. Yang H, Rotter JI. The genetics of inflammatory bowel disease. In Kirsner JB. editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 250-96.
30. Orchard TR, Satsangi J, Van Heel D, Jewell DP. Genetics of inflammatory bowel disease: a reappraisal. Scand J Immunol 2000;51:10-7.
31. Orholm M, Binder V, Sorensen TI, et al. Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol 2000;35:1075-81.
32. Thompson NP, Driscoll R, Pounder Re, et al. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996;312:95-6.
33. Tysk C, Lindberg G, Jarnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic twins and dizygotic twins: a study of heritability and the influence of smoking. Gut 1988;29:990-6.
34. Breslin NP, Todd A, Kilggallen C, O'Morain C. Monozygotic twins with Crohn's disease and ulcerative colitis: a unique case report. Gut 1997;41:557-60.
35. Brant SR, Panhuysen CIM, Bailey-Wilson JE, et al. Linkage heterogeneity for the IBD 1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology 2000; 119:1483-90.
36. Parkes M, Barmada MM, Satsangi J, Weeks DE, Jewel DP, Duen RH. The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn's disease. Am J Hum Genet 2000;67:1605-10.
37. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3.
38. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7, and 12. Nat Genet 1996;14:199-202.
39. Hampe J, Shaw SH, Saiz R, et al. Linkage of inflammatory bowel disease to chromosome 6p. Am J Genet 1999;65: 1647-55.
40. Ogura Y, Bowen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
41. Jobin C, Sartor RB. NF-κB signaling proteins as therapeutic targets doe inflammatory bowel diseases. Inflamm Bowel Dis 2000;6:206-13.
42. Hyams JS. Inflammatory bowel disease. Pediatr Rev 2000; 21:291-5.
43. Walker-Smith JA. Chronic inflammatory bowel disease in children: a complex problem in management. Postgrad Med J 2000;76:469-72.
44. Markowitz J, Grancher K, Rosa J, et al. Highly destructive perianal disease in children with Crohn's disease. J Pediatr Gastroentrol Nutr 1995;21:149-53.
45. Wilschanski, M Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995; 22:1415-22.
46. Floreani A, Zancan L, Melis A, Baragiotta A, Chiaramonte M. Primary sclerosing cholangitis (PSC): clinical, laboratory and survival analysis in children and adults. Liver 1999;19: 228-33.
47. Faubion WA Jr, Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric "psc-ibd": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001;33:296-300.
48. Koutroubakis IE. Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig Dis 2000;18:161-7.
49. Weber P, Husemann S, Vielhaber H, et al. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999;28:418-22.
50. Kirschner BS. The medical management of Crohn's disease in children. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 578-97.
51. Kjeldsen J, Lauritsen K, De Muckadell OB. Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Scand J Gastroenterol 1997;32:933-41.
52. Tibble JA, Siggthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
53. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999;353:459-61.
54. Dionne S, Hiscott J, D'Agata I, et al. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997;42:1557-66.
55. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
56. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9.
57. Hoffenberg EJ, Fidanza S, Sauaia A. Serological testing for inflammatory bowel disease. J Pediatrics 1999;134:447-52.
58. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2000;120: 827-33.
59. Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001;96:758-65.
60. Targan SR, Landers CJ, Cobb L, et al. Perinuclear antineutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunology 1995;155:3262-7.
61. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Taragan SR, Braun J. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immunol 2000;68:1542-8.
62. Ali SI, Carty HML. Paedatric Crohn's disease: a radiological review. Eur Radiology 2000;10:1085-94.
63. Hussain SM, Outwater EK, Joekes EC, et al. Clinical and MR imaging features of cryptoglandular and Crohn's fistulas and abscesses. Abdom Imaging 2000;25:67-74.
64. Charron M. Pediatric inflammatory bowel disease imaged with Tc-99m white blood cells. Clin Nucl Med 2000;25:708-15.
65. Seidman EG. Recent advances in the diagnosis and treatment of pediatric inflammatory bowel disease. Curr Gastroenterol 2000;2:248-52.
66. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000;119:1203-8.
67. Hanauer SB, Kane S. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 510-28.
68. Hanauer SB. Medical therapy for ulcerative colitis. In Kirsner JB. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders, 2000. p. 529-56.
69. Lang KA, Peppercorn MA. Medical therapy for Crohn's disease. In Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 557-77.
70. Green JT, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis: The Abacus investigator group. Gastroenterology 1998;114:15-22.
71. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease: Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1991;331:836-41.
72. Rutgeerts P. The use of budesonide in the treatment of active Crohn's disease is good clinical practice. Inflamm Bowel Dis 2001;7:60-1.
73. Kundhal P, Zachos M, Holmes JL, Griffiths AM. Controlled ileal release budesonide in pediatric crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 2001;33: 75-80.
74. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease-an historical and analytical review. Inflamm Bowel Dis 1998;4:29-39.
75. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
76. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998;12:53-6.
77. Jick S. Ciprofloxacin safety in a pediatric population. Ped Infect Disease J 1997;16:130-4.
78. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118(Suppl):S68-82.
79. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
80. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits out-weigh the risk if lymphoma. Gastroenterology 2000;118: 1018-24.
81. Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterology 2000;119:1132-47.
82. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
83. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenics and metabolite measurements for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;188: 705-13.
84. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-labeled pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181-9.
85. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
86. Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Ann Rev Med 2001;52:299-318.
87. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001;15:35-44.
88. Yang YX, Lichtenstein GR. Methotrexate for the maintenance of remission in Crohn's disease. Gastroenterol 2001; 120:1553-5.
89. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North America Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
90. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 2000;6:16-20.
91. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic implications. Gastroenterology 2000;119: 1148-57.
92. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatrics 2000;137:192-6.
93. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease. Gastroenterology 1999;117:1271-7.
94. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000; 119:1473-82.
95. Fuss IJ, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of TH1 T cells in experimental colitis. Gastroenterology 1999;117:1078-88.
96. Telander RL, Spencer M, Perrault J, Telander D, Zinsmeister AR. Long-term follow-up of the ileoanal anastomosis in children and young adults. Surgery 1990;108:717-23.
97. Muir AJ, Edwards LJ, Sanders LL, et al. A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001;96:1480-5.
98. Dietz DW, Laureti S, Strong SA, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surg 2001;192: 330-7.
99. Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol 2001;32:409-12.
100. Cima RR, Pemberton JH. Surgical management of inflammatory bowel disease. Curr Treatment Options Gastroenterol 2001;4:215-25.
101. Ruemmele FM, Roy CC, Levy F, Seidman EG. Nutrition as primary therapy in pediatric Crohn's disease: fact or fantasy? J Pediatrics 2000;136:285-91.
102. Sentongo TA, Semeao EJ, Piccoli DA, et al. Growth, body composition, and nutritional status in children and adolescents with Crohn's disease. J Pediatr Gastroenterol Nutr 2000;31:33-40.
103. Dieleman LA, Heizer WD. Nutritional issues in inflammatory bowel disease. Gastro Clin North Am 1998;27:435-51.
104. Heuschkel RB, Walker-Smith JA. Enteral nutrition in inflammatory bowel disease of childhood. J Parenter Enteral Nutr 1999;23(Suppl):S29-32.
105. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31:8-15.
106. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-67.
107. Fell JME, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine RNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9.
108. Belluzzi A, Boschi S, Brignola C, et al. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr 2000;71(suppl):339S-342S.
109. Semeao EJ, Jawad AF, Stouffer NO, et al. Risk factors for low bone mineral density in children and young adults with Crohn's disease. J Pediatrics 1999;135:593-600.
110. Haderslev KV, Tjellsen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-46.
111. Ferry GGD. Quality of life in inflammatory bowel disease: background and definitions. J Pediatr Gastroenterol Nutr 1999;28:S15-8.
112. MacPhee M, Hoffenberg EJ, Feranchuk A. Quality-of-life factors in adolescent inflammatory bowel disease. Inflamm Bowel Dis 1998;4:6-11.
113. Siegl WM, Golden NH, Gough JW, Lashley MS, Sacker IM. Depression, self-esteem, and life events in adolescents with chronic disease. J Adoles Health Care 1990;11:501-4.
114. Gortmaker SL, Walker DK, Weitzman M, Sobol AM. Chronic conditions, socioeconomic risks, and behavioral problems in children and adolescents. Pediatrics 1990;85:267-76.
115. Warren RW. A framework of health status and medical care for children with special health care needs [thesis]. Houston: The University of Texas Health Science Center at Houston, School of Public Health; 1995.
116. Griffiths AM, Nicholas D, Smith C, et al. Development of a quality of life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type. JPGN 1999;28:S46-52.
117. Schultz M, Sartor RB. Probiotics and inflammatory bowel disease. Am J Gastroenterol 2000;95(Suppl):S19-21.
118. Davidson GP, Butler RN. Probiotics in pediatric gastrointestinal disorders. Curr Opin Pediatr 2000;12:477-81.
119. Vanderhoof JA. Probiotics and intestinal inflammatory disorders in infants and children. J Pediatr Gastroenterol Nutr 2000;30 (Suppl 2):S34-38.
120. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
121. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999;352:635-9.
122. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
123. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1403-9.